Women were less than half of the people tested for almost all of these common medicines.
PregnancyCommunity forum

NCT00311155

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

See it on ClinicalTrials.gov ↗

694 people

337 womenmiddle line = equal numbers357 men
Phase
PHASE4
Paid for by
Sankyo Pharma Gmbh
Finished
2008-04
Health conditions
Essential Hypertension
Who could join
Anyone
Ages
18 Years – no maximum
Average age
mean 58.16 years
Age 65+
Not reported
Weight (BMI)
mean 28.86 kg/m^2
Pregnancy recorded
Not reported
Menopause recorded
Not reported
Results shown by sex
Not split by sex
Race
Not reported

Women left out

  • No pregnant women

    Women who were pregnant could not join.

    “Female patients of childbearing potential must not be pregnant or lactating and must be using adequate contraception.”
  • No breastfeeding moms

    Women who were breastfeeding could not join.

    “Female patients of childbearing potential must not be pregnant or lactating and must be using adequate contraception.”
  • Had to use birth control

    Women who couldn't or didn't want to use birth control were turned away.

    “Female patients of childbearing potential must not be pregnant or lactating and must be using adequate contraception.”
  • No kidney or liver problems

    Women with kidney or liver problems were turned away.

    “Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome.”
  • No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    “Patients within the last 6 months having a history of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, heart failure, cerebrovascular accident, or transient ischemic attack.”
  • No mental health conditions

    Women with depression, bipolar disorder or other mental health conditions were turned away.

    “…ich may limit the ability to evaluate the efficacy or safety of the test drug(s), including cardiovascular, renal, pulmonary, hepatic, gastrointestinal, endocrine/metabolic, haematological/oncological, neurological and psychiatric diseases.”
  • No cancer

    Women with current or past cancer were turned away.

    “…ich may limit the ability to evaluate the efficacy or safety of the test drug(s), including cardiovascular, renal, pulmonary, hepatic, gastrointestinal, endocrine/metabolic, haematological/oncological, neurological and psychiatric diseases.”

Study titles and rules are shown in their original English.